Evidence map›Paper›PMID 38651177›Full record

ArticleCancer medicine2024

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.

Katarina Uttervall, Love Tätting, Konstantinos Lemonakis, Mousa Majd, Jacob Crafoord, Mikael Olsson, Ulf-Henrik Mellqvist, Markus Hansson, Hareth Nahi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 5 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 5 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Katarina UttervallCenter for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-9786-6876
Love TättingDepartment of Haematology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.ORCID 0000-0001-8205-4712
Konstantinos LemonakisDepartment of Hematology, Lund University, Lund, Sweden.
Mousa MajdCenter for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Jacob CrafoordDepartment of Medicine, Orebro University Hospital, Orebro, Sweden.
Mikael OlssonSection of Hematology Department of Internal Medicine, Hallands Sjukhus Varberg, Varberg, Sweden.
Ulf-Henrik MellqvistSection of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Markus HanssonSection of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Hareth NahiCenter for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SELinköping University · SESahlgrenska University Hospital · SELund University · SEÖrebro University Hospital · SEVarberg Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T-cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections. METHODS/

resultsThis study evaluated the efficacy and safety of BCMA T-cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression-free survival at 15 months.

conclusionsDespite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real-world data highlight the potential of BCMA T-cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks.

Indexed as

Antibodies, BispecificB-Cell Maturation AntigenMultiple MyelomaAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalFemaleHumansMaleMiddle AgedProgression-Free SurvivalSwedenT-LymphocytesTreatment OutcomeAntibodies, BispecificAntineoplastic Agents, ImmunologicalB-Cell Maturation AntigenTNFRSF17 protein, humanbispecific antibodiesimmunotherapymultiple myelomareal‐world data

Identifiers

PMID38651177
PMCPMC11036077
OpenAlexW4395052190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.